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Abstract
Background: In view of rapidly increasing prescription costs, case-mix adjustment should be considered for effective
control of costs. We have estimated the variability in pharmacy costs explained by ACG in centers using patient
electronic records, profiled centers and physicians and analyzed the correlation between cost and quality of prescription.
Methods: We analyzed 65,630 patient records attending five primary care centers in Spain during 2005. Variables
explored were age, gender, registered diagnosed episodes of care during 2005, total cost of prescriptions, physician and
center. One ACG was assigned to each patient with ACG case-mix software version 7.1. In a two-part model, logistic
regression was used to explain the incurrence of drug expenditure at the first stage and a linear mixed model that
considered the multilevel structure of data modeled the cost, conditional upon incurring any expense. Risk and efficiency
indexes in pharmacy cost adjusted for ACG were obtained for centers and physicians. Spearman rank correlation
between physician expenditure, adjusted for ACG, and a prescription quality index was also obtained. Pediatric and adult
data were analyzed separately.
Results: No prescription was recorded for 13% of adults and 39.6% of children. The proportion of variance of the
incurrence of expenditure explained by ACGs was 0.29 in adults and 0.21 in children. For adults with prescriptions, the
variance of cost explained by ACGs was 35.4%, by physician-center was 1.8% and age 10.5% (residual 52.3%). For
children, ACGs explained 22.4% of cost and physician-center 10.9% (residual 66.7%). Center efficiency index for adults
ranged 0.58 to 1.22 and for children 0.32 to 2.36.
Spearman correlation between expenditure and prescription quality index was -0.36 in family physicians (p = 0.019, N =
41) and -0.52 in pediatricians (p = 0.08, N = 12).
Conclusion: In our setting, ACG is the variable studied that explains more variability in pharmacy cost in adults
compared to physician and center. In children there is greater variability among physicians and centers not related to
case-mix. In our sites, ACG is useful to profile physicians and centers using electronic records in real practical conditions.
Physicians with lower pharmaceutical expenditure have higher scores for a prescription quality index.
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Prescription drug costs are rapidly increasing in most
countries. The pharmaceutical expenditure in Catalonia,
Spain is 25% of total health cost [1]. Since patient com-
plexity is a major determinant of expenditure, in order to
control drug costs more effectively and with equity, meth-
ods for case mix adjustment should be considered.
The adjusted clinical groups (ACGs) system was devel-
oped at the Johns Hopkins University in Baltimore [2,3].
It estimates individual health status and risk for health
service use based on age, gender and diagnoses assigned
over a defined time interval, typically one year. Each diag-
nosis is assigned to one of 32 aggregated diagnostic
groups (ADGs). Each ADG is a cluster of similar condi-
tions based on their expected impact on health services
resource consumption. Patients are then classified into
one ACG based on age, gender and constellation of ADGs.
Even though this system was developed in the USA, it has
been used and assessed in other countries. In Spain, most
of the studies available have been performed in experi-
mental conditions. There is little information on the util-
ity of the system in real conditions of the daily clinical
practice and using the physicians encounter data.
Recently, Primary Care centers in the Catalan Institute of
Health have substituted patient clinical records from
paper to electronic format. This makes it possible to test
the ACG system in real conditions.
Physicians are sometimes reluctant to accept a control of
their expenditure. It is often argued that a reduction in
cost implies a reduced quality of health care. But the selec-
tion of low cost health providers as compared with others
of higher cost does not necessarily mean health care serv-
ice is adversely affected [4]. In Spain, older medications
are usually cheaper than new drugs and their safety and
efficacy profile is often best known. Physicians might
accept better a control of their expenditure if they knew
that quality is not compromised.
In this study we have three aims: 1) to estimate the varia-
bility in prescription drug costs explained by ACG in cent-
ers using electronic patient records, 2) to profile centers
and physicians after adjusting for ACG, and 3) to analyze
the correlation between pharmacy costs adjusted for ACG
and quality of prescription.
Methods
Setting
This is a cross-sectional observational study. Data were
obtained retrospectively from electronic records in five
primary care centers. All family physicians and pediatri-
cians working in these centers for the whole year and their
patients who attended at least once during the period Jan-
uary to December of 2005 have been studied. The centers
are located in Baix Llobregat Centre, close to Barcelona
and are referred as center A (assigned population:
21,748), center B (15,848), center C (26,768), center D
(14,281) and center E (15,937). These centers have been
using exclusively electronic records (software OMI AP ver-
sion 6.0) for more than 2 years.
Data retrieval and processing
Data available per patient from electronic records was:
encrypted identity number, age, gender, registered diag-
nosed episodes of care during 2005, drug prescriptions
(type and amount), assigned physician (with an
encrypted identity code) and center. The diagnosed health
problems were coded with the International Classification
for Primary Care (ICPC-2). A file with the drug prices from
Catsalut, a public agency responsible for contracting and
paying for health services in Catalonia, Spain, was used to
obtain the cost of prescribed medication per patient (in
euros). Electronic printed prescriptions are an overestima-
tion of prescribed drugs that are obtained from the phar-
macy store and invoiced to Catsalut. A correction to the
patient prescription cost was applied according to the
deviation within each center of the prescription cost
obtained from electronic files and the real expenditure
invoiced.
A conversion (mapping) from ICPC-2 codes to ICD-9-CM
has been performed [5]. For this process a working team
(a documentalist, 2 clinical doctors and 2 consulters) was
created. There were three different groups according to the
relations among the two system codes: 1) no relation (one
code in ICPC-2 with no equivalent in ICD-9-CM), 2) uni-
vocal relation (one code in ICPC-2 had a single corre-
spondence in the ICD-9-CM, this was the optimal
situation) and 3) multiple relations (one code in ICPC-2
had several possible codes in ICD-9-CM). For codes in
group 1, the documentalist, with the agreement of the rest
of the team, codified the descriptors to the closest ICD-9-
CM category. For codes in group 3, if all possible ICD
codes had the same Adjusted Diagnostic Group, then this
ADG was adopted. But if several ADGs were possible, then
the most frequent ICD-9-CM code was considered.
From coded diagnoses of episodes, the Johns Hopkins
ACG case-mix system software version 7.1 classified sub-
jects into 32 binary (present/absent) Aggregated Diagno-
sis Groups (ADGs). In a second step, a single ACG
category was assigned to each patient based on age, gender
and the number and type of ADGs.
Each physician and center had a score for quality of pre-
scription assigned by a computerized program of the Cat-
alan Institute of Health. This institution has developed a
quality index for family physicians and for pediatriciansPage 2 of 11
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version available for 2005 [see Additional file 1]. In the
Catalan Institute of Health official web, the procedures for
the construction of the updated 2007 version is available
[6]. For family physicians the maximum score is 130 and
consists of general and specific indicators that consider
mostly the efficacy and safety, and also the efficiency of
therapeutic options for the most common conditions in
primary care. Global indicators include the use of generics
and new drugs, and specific indicators include the use of
non steroidal anti-inflammatory drugs, antibiotics and
drugs for hypertension, ulcer, hyperlipidemia, asthma,
depression, anxiety/insomnia and diabetes. Pediatricians
can have a maximum score of 70 according to global indi-
cators that include the use of generics and new drugs, and
specific indicators about the use of antibiotics and drugs
for asthma.
Statistical analysis
The distribution of ACG in the population was described
separately for pediatric (<15 years) and adults. ACGs with
similar mean cost were grouped in resource utilization
bands (RUBs) based on quintiles in order to have a
reduced number of homogeneous categories. We added
one to all values of cost data and then log transformed to
reduce the skewness of the distribution and make it close
to normal. Only one patient with an extremely high
expenditure was excluded from the analysis.
Variability in prescription drug expenditures
For univariate analysis, the coefficient of determination
(R2) derived from linear regression models was calculated
for variables expected to explain the variability in drug
expenditure. ACG, patient age, physician and center were
found to explain a significant proportion of the variance.
Physician and center characteristics thought to influence
drug expenditure like physician age, gender and assigned
population, or center size and teaching activities were
explored, but none was significant and were not further
considered. Then a multivariate analysis of the sources of
variability in pharmacy costs done using variance compo-
nents analysis derived from linear mixed models that con-
sidered the multilevel structure of data (physicians nested
within centers). The logarithm of the cost per patient was
modeled with the following formula:
log(cost) = α + β0·age + β1·age2 + ACGi + physi-
cian(center)j + εk
ACGi ~ N(0, σ21)
physician(center)j ~ N(0, σ22)
εk ~ N(0, σ23)
Age was fitted as a fixed effect, with linear and quadratic
terms. ACG and physician (nested within center) were
considered random effects. The values observed were sup-
posed to follow a normal distribution with zero mean and
a given variance. These variances (σ21 and σ22) were the
parameters of interest for the ACG and physician varia-
bles. The residual variance was also a relevant term,
because indicated the amount of variability unexplained
by these terms. The variances per se were not important,
because they depend on the actual data observed. We cal-
culated the relative contribution of each term to the total
variance as indicator of the importance of the variable in
the variability of pharmaceutical expenditure.
Since the calculation of ACGs considered age and gender,
including all these terms in the model would make diffi-
cult the interpretation due to colinearity. Gender was not
relevant in explaining cost, and we decided to exclude this
term, which would have a zero parameter. For age, we first
fitted a linear model with ACG as random effect and cal-
culated the residuals for each subject. The residuals can be
interpreted as the variability in age not accounted for
already in the ACGs terms. Then we used these residuals
in a linear and quadratic term as fixed effects in the mod-
els to explore the variability in cost. This way, the variance
component for age should be interpreted as that not
already explained by ACG. These models were estimated
using the restricted maximum likelihood method.
A two-part model was also used. In a first step, a binary
logistic regression using ACG as a covariate was applied to
predict the incurrence of drug expenditure. Nagelkerke R2
was used to estimate the proportion of variance explained.
We chose this measure knowing its limitations as an
approximation to the coefficient of determination in a lin-
ear model. In logistic regression models the concept of
residual variance is not easy to define because the
response variable is binary. These models are fitted by
maximum likelihood and the likelihood value can be
used as a relative measure of model fit. The problem is
that, when modeling individual data, as in our study, the
actual likelihood value depends on sample size and has
no interpretation. Nagelkerke [7] defined an equivalent
value to the coefficient of determination based on the
ratio of likelihoods between the "null" model (with only
a constant) and fitted model, appropriately corrected to
have a maximum of 1. This coefficient can be interpreted
as the goodness of the model in predicting the response
from the covariates, similar to R2 in linear regression. We
have assumed approximate additivity in the proportion of
variance explained by multiple factors, which is appropri-
ate when these are not too large.
In a second step of the two part model, the variability in
pharmacy costs restricted to patients with prescriptionsPage 3 of 11
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ear mixed models as before. ACGs with less than 30 sub-
jects were excluded from the analysis.
Profiling of centers and physicians
Risk and efficiency indexes in pharmacy costs, adjusted for
ACG, were obtained for centers and physicians. Risk index
or morbidity burden was calculated for each center and
physician. It shows the complexity of visited population
in relation to a standard and is calculated as the ratio
between the predicted mean pharmaceutical cost consid-
ering the ACG distribution and the mean pharmaceutical
cost of the whole population studied. Efficiency index
compares pharmaceutical expenditure among centers and
physicians assuming similar population complexity. It is
calculated as the ratio between the observed mean
expenditure and the predicted mean expenditure adjusted
for ACG. Expenditure of centers and physicians were com-
pared after adjusting for ACG using linear mixed models.
The Spearman rank correlation between physician phar-
macy cost adjusted for ACG and the prescription quality
index was calculated.
Results
Description of population and variables
A total of 55,971 adult and 9,659 pediatric patients have
been studied (table 1). The distribution of logarithmic
prescription drug expenditure is shown in figure 1. In
13.1% of adult patients and 39.6% of children there was
no expenditure. The expenditure of drug prescriptions
obtained from the pharmacy store and invoiced to the
health system was in average 24.7% lower than the
expenditure calculated from the printed prescriptions
according to the patient electronic records.
A total of 254,830 ADGs were assigned (52,909 in center
A, 64,639 in center B, 67,213 in center C, 35,987 in center
D and 34,082 in center E). After ranking ACGs by fre-
quency, 75% of patients were distributed in the first 19
(partially listed in table 2) and 90% in the first 34. ACGs
have been grouped in 6 homogeneous resource utiliza-
tion bands (RUBs) (table 3).
Explained variability in pharmaceutical expenditure
When considering individual variables (univariate analy-
sis), the proportion of variance explained (R2) of pharma-
ceutical expenditure was, for adult patients: 0.31 for age,
0.01 for gender, 0.03 for physician and 0.39 for ACG. For
pediatric patients R2 values were: 0.04 for age, 0 for gen-
der, 0.33 for physician and 0.19 for ACG. Between centers,
R2 for ACGs in adult population showed little variability
(0.32 to 0.45) while in pediatric patients the proportion
of cost explained by ACGs was smaller and more disperse
between centers (0.09 to 0.39).
In table 4 the results of applying linear mixed models to
estimate variance components for the whole population
for adults and children are presented. It also presents the
results from the two-part model, in which first the incur-
rence of expenditure was modeled with logistic regression
followed by a linear mixed model to estimate the compo-
nents of variance of the level of cost conditional upon
incurring any expense. It is noteworthly that while heter-
ogeneity among physicians explains little of adult expend-
iture, this factor is very relevant for pediatric expenditure,
and the proportion of explained variance is larger for the
incurrence of expenditure than for the cost. Supplemen-
tary tables give detailed estimates for these models overall
and for each center [see Additional file 2].
The observed and expected expenditure after adjusting for
ACG for each of the centers and the risk and efficiency
indexes are presented in table 5. In figure 2 the crude and
adjusted expenditures for each physician are represented.
It is apparent that the adjustment for ACGs reduces the
variability in mean expenditure.
Correlation between physician pharmaceutical 
expenditure and quality score
When using crude expenditure, in family physicians the
Spearman rank correlation was -0.18 (N = 41, p = 0.26)
and in pediatricians it was -0.54 (N = 12, p = 0.07). After
Table 1: Characteristics of the population.
Center Patients Median age Pharmaceutical expenditure Median (euros) Prescription quality score
Adults Pediatrics Adults Pediatrics Adults Pediatrics
A 13043 1940 42 34.5 7.2 106 62
B 9648 1644 43 42.5 2.8 86 29
C 16791 3045 38 36.1 14.6 77 11
D 8413 1671 40 36.5 0 90 62
E 8076 1359 43 44.8 0 63 66
Total 55971 9659 40 37.8 3.79Page 4 of 11
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Distribution of pharmaceutical expenditureFigure 1
Distribution of pharmaceutical expenditure. Distribution of prescription drug expenditure in pediatric population 
(above) and adults (below).
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adults was -0.36 (p = 0.019) and in pediatricians -0.52 (p
= 0.08).
Discussion
In this study we show that patient case-mix measured with
ACGs is the major determinant of pharmaceutical expend-
iture variability in our setting. Adjustment for ACGs
allows a much fair comparison of expenditures among
Table 2: More frequent ACGs and ACGs with more expenditure
ACG Description N % cumulate%
300 Acute Minor, Age 6+ 7087 10.8 10.8
4100 2–3 Other ADG Combinations, Age 35+ 6544 10 20.8
4910 6–9 Other ADG Combinations, Age 35+, 0–1 Major ADGs 4948 7.5 28.3
2100 Acute Minor/Likely to Recur, Age 6+, w/o Allergy 3763 5.7 34
4410 4–5 Other ADG Combinations, Age 45+, no Major ADGs 2878 4.4 38.4
1800 Acute Minor/Acute Major 2799 4.3 42.7
4420 4–5 Other ADG Combinations, Age 45+, 1 Major ADGs 2444 3.7 46.4
500 Likely to Recur, w/o Allergies 2333 3.6 50
3600 Acute Minor/Acute Major/Likely to Recur/Chronic Medical: Stable 2102 3.2 53.2
400 Acute Major 1860 2.8 56
3200 Acute Minor/Acute Major/Likely to Recur, Age 12+, w/o Allergy 1859 2.8 58.8
2300 Acute Minor/Chronic Medical: Stable 1704 2.6 61.4
1600 Preventive/Administrative 1522 2.3 63.7
4310 4–5 Other ADG Combinations, Age 18 to 44, no Major ADGs 1380 2.1 65.8
4920 6–9 Other ADG Combinations, Age 35+, 2 Major ADGs 1342 2 67.8
2500 Acute Minor/Psychosocial, w/o Psychosocial Unstable 1282 2 69.8
3500 Acute Minor/Likely to Recur/Psychosocial 1188 1.8 71.6
ACG Description mean expenditure RW
4940 6–9 Other ADG Combinations, Age 35+, 4+ Major ADGs 1674.5 6.1
5060 10+ Other ADG Combinations, Age 18+, 3 Major ADGs 1519.5 5.5
5050 10+ Other ADG Combinations, Age 18+, 2 Major ADGs 1397.4 5.1
4930 6–9 Other ADG Combinations, Age 35+, 3 Major ADGs 1358.6 4.9
5070 10+ Other ADG Combinations, Age 18+, 4+ Major ADGs 1278.6 4.6
4920 6–9 Other ADG Combinations, Age 35+, 2 Major ADGs 1049.3 3.8
5040 10+ Other ADG Combinations, Age 18+, 0–1 Major ADGs 924.0 3.3
4430 4–5 Other ADG Combinations, Age 45+, 2+ Major ADGs 884.8 3.2
1400 Psychosocial, w/Psychosocial Unstable, w/o Psychosocial Stable 755.1 2.7
4420 4–5 Other ADG Combinations, Age 45+, 1 Major ADGs 741.2 2.7
4910 6–9 Other ADG Combinations, Age 35+, 0–1 Major ADGs 703.0 2.5
800 Chronic Medical: Unstable 630.6 2.3
2700 Acute Minor/Psychosocial, w/Psychosocial Unstable/Psychosocial Stable 617.7 2.2
4730 6–9 Other ADG Combinations, Males, Age 18 to 34, 2+ Major ADGs 615.1 2.2
More frequent ACG categories (above) and ACG with higher relative weights (RW) for pharmaceutical expenditure (below).
Table 3: Distribution in Resource Utilization Bands (RUBs)
RUB 1 RUB 2 RUB 3 RUB 4 RUB 5 RUB 6
Median expenditure 0 1.9 7.4 27.8 135 468.3
Center A 5.6 5.2 38.6 15.6 23.4 11.6
Center B 3.6 1.3 25.3 22.9 17.0 30.0
Center C 2.1 4.3 41.1 20.3 17.2 14.9
Center D 4.4 5.0 42.4 16.5 20.1 11.8
Center E 0.4 2.7 35.2 21.9 21.1 18.7
Total 3.2 3.8 37.2 19.3 19.6 16.8
Percent distribution of patients in resource utilization bands. Median pharmaceutical expenditure (in euros) for each band.Page 6 of 11
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expenditure correlates negatively with a prescription qual-
ity index more strongly when adjusted for ACGs, which
can be interpreted as evidence that, when complexity of
the patients is accounted for, better quality of prescription
is associated with lower expenditure.
Table 4: Cost modeling approaches for prediction of pharmaceutical expenditure.
Total population Two-part model
Expenditure incurrence Level of expenditure
Linear mixed models Logistic regression Linear mixed models
Adult population
Fixed effects V SE %V %EV V SE %EV
Age* 1.4% 0.6% 10.5% 10.5%
Random factors
ACG 5.01 0.89 44.7% 28.8% 2.78 0.49 35.4%
Physician (center) 0.27 0.06 2.4% 1.5% 0.14 0.03 1.8%
Residual 5.77 0.04 51.5% 69.1% 4.11 0.03 52.3%
Total 11.21 100% 100% 7.85 100%
Pediatric population
Fixed effects V SE %V %EV V SE %EV
Age* 0.1% 0.4% 0.0%
Random factors
ACG 1.22 0.28 22.2% 20.6% 0.66 0.17 22.4%
Physician (center) 1.62 0.69 29.5% 38.8% 0.32 0.14 10.9%
Residual 2.66 0.04 48.3% 40.2% 1.98 0.04 66.7%
Total 5.51 100% 100% 2.96 100%
Statistical tests applied to the total population and two-part model. Linear mixed models include: estimation of variance (V), standard error (SE) and 
percentage of explained variance (%EV).
* Age fixed effects include linear and quadratic terms.
Table 5: Risk and efficiency index for centers.
Family physicians
Center Observed expenditure Expected expenditure Risk Index Efficiency Index
A 37.94 32.80 0.78 1.16
B 46.14 79.84 1.90 0.58
C 41.18 36.62 0.87 1.12
D 41.80 34.21 0.81 1.22
E 46.85 51.57 1.23 0.91
Total 41.99 41.99 1.00 1.00
Pediatricians
Center Observed expenditure Expected expenditure Risk Index Efficiency Index
A 7.28 5.00 0.97 1.46
B 4.34 6.02 1.16 0.72
C 13.09 5.56 1.07 2.36
D 1.25 3.93 0.76 0.32
E 2.70 5.45 1.05 0.50
Total 5.18 5.18 1.00 1.00
Mean pharmaceutical expenditure per visited patient, observed and expected according to ACGs distribution (in euros).Page 7 of 11
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Family physicians pharmaceutical expenditureigure 2
Family physicians pharmaceutical expenditure. Prescription drug expenditure for family physicians, crude (above) and 
adjusted for ACGs (below).
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lyzed separately because their distribution is different and
the proportion of expenditure variance explained for the
main factors is also different. In adults, the expenditure is
higher. A significant percentage of patients attended the
centers but had no prescription (13%, figure 1). The dis-
tribution of the logarithmic expenditure looks like a mix-
ture of two overlapped normal populations. Possibly this
shape is due to the patients with chronic medication that
have higher costs, but we have no data to prove it because
this variable was not available. In pediatric patients, the
proportion attending the centers without prescription is
higher, 40% and the distribution of the logarithmic
expenditure looks like a single normal population.
Healthcare cost data usually have mixed distributions
with a high percentage of non-users and a right-skewed
distribution for users [8]. Two-part modeling has been
used to address the issue of a mixed distribution of data.
This approach first estimates the probability of incurring
any cost and subsequently models the amount of cost
conditional on having incurred any cost [9]. ACG explain
28.8% of the variability in the incurrence of drug prescrip-
tions in adults and 20.6% in children. In subjects with
prescriptions, the variability in expenditure explained by
ACG accounts for 35.4% in adults and 22.4% in children.
We should emphasize that the results obtained here are
site specific and need not generalize to other sites with dif-
ferent patient population profiles, non-primary care set-
tings or structure of care provision. However, these results
are similar to those obtained by other authors in real prac-
tice conditions. Orueta [10] in the Basque Country, Spain
proved ACG was useful in real conditions of daily practice
to explain 50% of the variance in visits to primary care
physicians, 25 – 40% of prescriptions, 25 – 30% of refer-
rals and requests of laboratory tests and 14–16% of radi-
ographs. The coefficients of determination remained
almost invariable after the addition of hospital diagnosis
or correction of coding errors by the research team. Sicras
[11] found that 20% of the variability in pharmacy costs
was explained by ACGs in a non-public primary care
health center in Catalonia, Spain, using a retrospective set-
ting.
Only one patient with extremely high expenditure was
excluded from the analysis. No other data were truncated
to remove the effect of outliers. This would have improved
the fit of the models. But a small proportion of the popu-
lation accounts for a large amount of pharmaceutical
expenditure [12]. So if data are not truncated, the ability
to predict pharmacy costs for the patients with the highest
expenditures that often contribute a disproportionate
amount of total cost is preserved.
More than half of the variability in prescription drug
expenditure still remains to be explained. Context varia-
bles, summarized in center, show little impact in variabil-
ity. And physician related factors are only relevant in
pediatric population. Some other variables not recorded
and measurement error may play a role in the observed
variability. The accumulation of different kind of errors
may be heterogeneous among centers and professionals.
The main sources of errors are: deficient quality in patient
record files, errors in diagnostic coding and in recoding
from ICPC-2 to ICD-9-MC. Our source of information for
prescription cost was the patient electronic files, which
records information of printed prescriptions. This is an
overestimation of real cost invoiced to the health system
for several reasons: a prescription might be printed several
times because of technical problems. Also, not all patients
with a prescription go to the pharmacy store to get the
drug. As a result of this, the real pharmacy cost invoiced to
the health system is not as high as that obtained from the
patient electronic file. In our study we estimated a devia-
tion of 25%, and an appropriate correction was applied
when estimating the sources of variability. Although the
deviation is important, and it is a limitation of the study,
we cannot analyse in detail these unfilled prescriptions
because the real cost per person invoiced to the health sys-
tem is not available. Only the global deviation per center
was available and that is what we used for correction.
ACG system has proved useful in the profiling of centers
and physicians when data are obtained from electronic
records in real conditions of usual practice. It is possible
to identify physicians and centers with high expenditure
but with a good efficiency index after adjusting for case-
mix. Also some centers and professionals have an appar-
ent low cost but considering their case mix, a lower
expenditure would be expected.
In center B, the median expenditure per visited patient in
adults is one of the highest. After adjusting for ACG, it
becomes apparent the population visited has more bur-
den of morbidity (risk index 1.9) and has the best effi-
ciency index (0.58). On the other hand, center A has the
lowest median expenditure per patient in adults. After
adjusting for ACG, the population has the lowest burden
of morbidity (risk index: 0.78) and the efficiency is less
than satisfactory (efficiency index: 1.16). When consider-
ing the median expenditure per pediatric patient, center C
has an extremely high value. After adjusting for ACG, the
burden of morbidity of their patients is slightly above
average and the efficiency index is very poor (an index of
2.36). Similar observations can be performed considering
each physician's prescription. Other authors have also
used ACG system for profiling of physicians and showed
similar results [13,14].Page 9 of 11
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median of 0 per paediatric patient (table 1). As it is evi-
dent in table 5, the mean observed cost for paediatric
patient in sites D and E patient is lower than the expected
expenditure according to ACG distribution, and so the
efficiency index in these centers is better. Globally in our
setting, 40% of total children had no prescription and
there was a high variability in cost explained by physician
and center. In paediatric care, the case-mix does not
account for so much variability in prescription cost as in
adults. Most of the children visited in primary care setting
have not serious diseases and there seems to be a different
prescription approach according to the physician
involved.
It is important to check that the quality of care is not com-
promised when expenditure is controlled. In fact, family
physicians with higher quality scores have lower expendi-
ture and this correlation is improved after adjusting for
ACGs. The number of pediatricians studied is very low (N
= 12), but still the Spearman rank correlation approaches
a significant value. In this case, adjusting for ACG does
not improve the correlation. Medications with a long time
in the market usually have a lower cost than new drugs.
Older medications often have a better known safety and
efficacy profile. Because quality is not reduced when pre-
scription cost is low, it might be easier for physicians to
accept a control of their expenditure.
Conclusion
In our setting, case-mix, measured with the ACG system,
is the variable studied that explains more variability in
prescription drug expenditure in adults. In pediatric pop-
ulation there is greater variability among physicians and
centers which is not related to case-mix. The implementa-
tion of clinical guidelines might be helpful to reduce this
variability.
For our sites, ACG is a useful tool to analyze efficiency and
compare physicians and centers when data are obtained
from electronic records in real conditions of usual prac-
tice. It is possible to identify physicians and centers with
high expenditure but with a good efficiency index after
adjusting for case-mix, and also centers and professionals
with apparent low cost but considering their case mix, a
lower expenditure would be expected. Physicians with
lower pharmaceutical expenditure have higher scores for
the prescription quality index studied and in adult popu-
lation the correlation increases when expenditure is
adjusted for ACG.
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